Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT ID: NCT00859027
Last Updated: 2018-05-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2003-01-31
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
NCT00426777
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
NCT00216060
Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density
NCT00145704
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
NCT00092014
Risedronate in Postmenopausal Women With Low Bone Density
NCT00351091
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Risedronate
35 mg by mouth every week as directed
risedronate
35 mg/week by mouth
risedronate placebo tablet
Calcium and vitamin D
Placebo risedronate oral tablet
One tablet by mouth every week as directed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
risedronate
35 mg/week by mouth
Placebo risedronate oral tablet
One tablet by mouth every week as directed
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men to receive Gonadotropin-releasing Hormone-agonist therapy
Exclusion Criteria
* Evidence of metabolic bone disease
* Prior use of bisphosphonates
55 Years
85 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Proctor and Gamble/Aventis
UNKNOWN
UConn Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pamela Taxel
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pamela Taxel, MD
Role: PRINCIPAL_INVESTIGATOR
UConn Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Connecticut Health Center
Farmington, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GCRC # 413
Identifier Type: -
Identifier Source: secondary_id
None given
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
None given
Identifier Type: OTHER
Identifier Source: secondary_id
02-062
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.